• China has set out on a long-term plan to tackle spiralling health costs.

• Government has been targeting drug categories with strong local players and striking new deals to lower procurement costs.

• Success of procurement policies means pharmacies are set to have a much greater role with rise of Direct To Patient (DTP) products.

• New procurement models now moving into medical devices, but challenges remain in this sector.

• Multinationals need to respond to new playing field with a renewed focus on innovation, and by revamping their own supply chains.

About InterChina

InterChina is a leading strategy and corporate finance boutique specialized in China. Healthcare is one of our core sectors of expertise with consultants and advisors dedicated to the space. Our multinational and Chinese clients choose to work with us because we provide real understanding, deliver practical results, and know how to get things done. We are a partner led firm and distinguish ourselves by the deep level of engagement partners have in client engagements.

Rick Woo
Principal, InterChina
Rick.Woo@InterChinaConsulting.com